(March 21, 2016, 1:53 PM EDT) -- WASHINGTON, D.C. — Acting on interlocutory appeal, the Federal Circuit U.S. Court of Appeals on March 18 affirmed findings by two Delaware federal judges that Mylan Pharmaceuticals Inc. must face patent infringement allegations in Delaware based on Mylan’s lawsuit-related contacts there (Acorda Therapeutics Inc., et al. v. Mylan Pharmaceuticals Inc., No. 15-1456; AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 15-1460, Fed. Cir.; 2016 U.S. App. LEXIS 4942)....